Revvity (RVTY) said Friday the Food and Drug Administration has cleared EUROIMMUN's automated chemiluminescence-based immunoassay test, which is used for measuring free testosterone levels.
The test is the first FDA-cleared assay for direct measurement of free testosterone in human serum or plasma, the company said.
Revvity said that the test delivers results in 48 minutes with a output of nearly 60 tests per hour.
The assay is designed to diagnose androgen disorders, including hypogonadism, impotence, and polycystic ovarian syndrome, Revvity said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.